16.09.2021
When and how should age influence treatment
Session Track
Head and neck cancer, excl. thyroid
08:30 – 09:20 Type: Educational session Title: The emerging role of immunotherapy in the curative setting
08:35 – 08:50 Immune landscape in head and neck cancer: Rationale and opportunities for integrating immunotherapy in curative treatment protocols
17.09.2021
Time: 17:30 – 18:30
Location: Channel 3
860MO – Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC)
862MO – Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer
865MO – RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation
e-Posters:
869P – Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results of a pilot study
Presentation Number
869P
928TiP – Induction versus adjuvant gemcitabine/cisplatin in locally advanced non-metastatic nasopharyngeal carcinoma: A randomised phase III trial
Presentation Number
928TiP
